CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $12.76B, above the global median of $1.15B
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.76BUSDvs all stocks (USD)
Revenue (TTM)
1.13BUSDvs all stocks (USD)
Profit Margin
-27.32%vs Biotechnology peers
Beta
-1.06xvs all stocks
52-Week Change
67.24%vs all stocks
Market Capitalization
12.76BUSDvs all stocks (USD)
Enterprise Value
12.30BUSDvs all stocks (USD)
Forward P/E
44.71xvs Biotechnology peers
Price to Sales (TTM)
11.27xvs Biotechnology peers
Price to Book (MRQ)
23.47xvs Biotechnology peers
Enterprise to Revenue
10.86xvs Biotechnology peers
Enterprise to EBITDA
-39.41xvs Biotechnology peers
Gross Margin
91.38%vs Biotechnology peers
Profit Margin
-27.32%vs Biotechnology peers
Operating Margin
-29.78%vs Biotechnology peers
Return on Assets (TTM)
-17.62%vs Biotechnology peers
Return on Equity (TTM)
-49.35%vs Biotechnology peers
Revenue (TTM)
1.13BUSDvs all stocks (USD)
Revenue per Share (TTM)
49.95USDUpdated Jul 19, 2026Quarterly Revenue Growth
126.80%vs Biotechnology peers
Gross Profit (TTM)
1.05BUSDvs all stocks (USD)
EBITDA (TTM)
-312.00MUSDvs all stocks (USD)
Net Income (TTM)
-309.44MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
126.84%vs Biotechnology peers
Operating Cash Flow (TTM)
-268.10MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-156.40MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
958.40MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
56.15MUSDFY2025 · Dec 31, 2025Gross Profit
902.25MUSDFY2025 · Dec 31, 2025Operating Income
-300.10MUSDvs all stocks (USD)
Pre-tax Income
-288.28MUSDFY2025 · Dec 31, 2025Net Income
-288.28MUSDFY2025 · Dec 31, 2025EBIT
-265.98MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-261.69MUSDFY2025 · Dec 31, 2025Research & Development
388.52MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
813.83MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
37.36MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
22.31MUSDFY2025 · Dec 31, 2025EPS (Basic)
-12.85USDFY2025 · Dec 31, 2025EPS (Diluted)
-12.85USDFY2025 · Dec 31, 2025Basic Shares Outstanding
22.43MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
22.43MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-288.28MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-296.19MUSDFY2025 · Dec 31, 2025Free Cash Flow
-296.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
203.78MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-288.28MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
98.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.81MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-80.65MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
5.28MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-36.98MUSDFY2025 · Dec 31, 2025Capital Expenditures
-467.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-1.05BUSDFY2025 · Dec 31, 2025Sale of Investments
1.08BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
35.32MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
350.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-121.66MUSDFY2025 · Dec 31, 2025Other Financing Charges
-10.41MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
217.93MUSDFY2025 · Dec 31, 2025Shares Outstanding
23.04MSharesUpdated Jul 19, 2026Float Shares
14.00MSharesUpdated Jul 19, 2026Shares Short
3.53MSharesUpdated Jul 19, 2026Short Ratio
8.54daysvs all stocks
Short % of Shares Outstanding
17.99%vs all stocks
% Held by Insiders
5.68%vs all stocks
% Held by Institutions
106.99%vs all stocks
Total Cash (MRQ)
812.77MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
35.25USDUpdated Jul 19, 2026Total Debt (MRQ)
347.31MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6391xvs Biotechnology peers
Current Ratio (MRQ)
3.50xvs Biotechnology peers
Book Value per Share (MRQ)
23.59USDUpdated Jul 19, 2026Total Assets
1.26BUSDvs all stocks (USD)
Total Current Assets
1.25BUSDFY2025 · Dec 31, 2025Total Liabilities
656.90MUSDFY2025 · Dec 31, 2025Total Non-current Assets
13.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
346.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
310.29MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
198.69MUSDFY2025 · Dec 31, 2025Other Short-term Investments
784.87MUSDFY2025 · Dec 31, 2025Accounts Receivable
134.48MUSDFY2025 · Dec 31, 2025Inventory
74.84MUSDFY2025 · Dec 31, 2025Accounts Payable
48.88MUSDFY2025 · Dec 31, 2025Short-term Debt
1.02MUSDFY2025 · Dec 31, 2025Long-term Debt
346.61MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.09BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
602.69MUSDvs all stocks (USD)
52-Week Low
286.44USDUpdated Jul 19, 202652-Week High
615.00USDUpdated Jul 19, 202652-Week Change
67.24%vs all stocks
Beta
-1.06xvs all stocks
50-Day MA
514.41USDUpdated Jul 19, 2026200-Day MA
502.73USDUpdated Jul 19, 2026Avg 10-Day Volume
325.11KSharesUpdated Jul 19, 2026Avg 30-Day Volume
384.04KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-13.50USDUpdated Jul 19, 2026Other Income / Expense
-3.24MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.91Profit Margin: -0.27
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.57
Altman Z-Score 10.29: safe zoneNotable
Altman Z-Score: 10.29
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $12.76B, above the global median of $1.15BNotable
Market cap (USD): 12,760,845,682Global Median: 1,146,734,693.424
Revenue is $1.13B, above the global median of $520.53MNotable
Revenue (USD): 1,132,489,984Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Elanco Animal Health Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Swedish Orphan Biovitrum AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai United Imaging Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Penumbra Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yunnan Baiyao Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang NHU Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Axsome Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC